Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy and cranial radiotherapy followed by tislelizumab plus temozolomide maintenance in extensive-stage small cell lung cancer with brain metastases
ChiCTR2500095772Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, temozolomide, etoposide, carboplatin and cisplatin in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: 6-month progression-free survival rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
tislelizumabtemozolomideetoposidecarboplatincisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500095772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095772.